In 2018 Pembrolizumab received an accelerated FDA approval for PD-L1 positive advanced cervical cancer (combined positive score > 1) with progression following chemotherapy due to the fascinating results of the KEYNOTE-158 trial in heavily pretreated patients [26, 27]. This evidence concerns the gene CD274 and cervical cancer.